AR
PCVX icon

Advisory Research’s Vaxcyte PCVX Stock Holding History

Advisory Research’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,461
Closed -$1.1M – 275
2023
Q4 		$1.1M Sell
17,461
-23,794
-58% -$1.24M 0.17% 150
2023
Q3 		$2.1M Buy
41,255
+6,537
+19% +$322K 0.29% 95
2023
Q2 		$1.73M Buy
+34,718
New +$1.65M 0.22% 120
2023
Q1 		– Sell
-4,304
Closed -$206K – 395
2022
Q4 		$206K Buy
+4,304
New +$169K 0.02% 336

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Advisory Research's PCVX Position: Q1 2024 in Review

Advisory Research sold out of Vaxcyte (PCVX) in Q1 2024, closing a stake of 17,461 shares — an estimated $1.1M sold.

Advisory Research first reported a position in PCVX in Q4 2022 and held it in 4 quarters. The position peaked at $2.1M in Q3 2023. 251 funds tracked by Wall St. Rank hold PCVX as of Q1 2024.

  • Advisory Research reported no remaining Vaxcyte position as of Q1 2024 after selling out during the quarter.
  • Advisory Research sold 17,461 Vaxcyte shares in Q1 2024, an estimated $1.1M.
  • Advisory Research first reported a position in Vaxcyte in Q4 2022 and held it in 4 quarters.
  • Advisory Research's Vaxcyte position peaked at $2.1M in Q3 2023.
  • 251 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2024.

Based on Advisory Research's 13F filing for Q1 2024, filed 14 May 2024.